How C$81 Bought Control of a Nasdaq Biotech: Inside Quantum BioPharma's Survival Playbook

TORONTO, ON – November 11, 2026 — In the high-stakes arena of biopharmaceutical development, securing a controlling interest in a Nasdaq-listed company usually requires a war chest of millions, an army of investment bankers, and months of grueling negotiations. But occasionally, the mechanics of corporate governance allow for a different path entirely. On Monday, the leadership of Quantum BioPharma Ltd. tightened their grip on the company's voting power to a dominant 68.22%.

The cost of this consolidation? A mere C$80.86.

The transaction, announced alongside the results of the company's annual general and special meeting (AGSM), highlights a fascinating and increasingly scrutinized intersection of capital markets, insider control, and biotech survival. As Quantum BioPharma advances a promising Phase 2 drug for multiple sclerosis, its boardroom maneuvering offers a masterclass in how microcap companies engineer their defenses against market volatility and delisting threats.

The Mechanics of a C$81 Supermajority

To understand how less than a hundred Canadian dollars buys control of a public company, one must look at Quantum BioPharma's dual-class share structure. The company operates with standard Class B Subordinate Voting Shares, which trade on the Nasdaq, and a highly concentrated tier of Class A Multiple Voting Shares.

Each Class A share carries an astonishing 276,660 votes.

On November 9, the company closed a non-brokered private placement of just 26 of these Class A shares at C$3.11 each. The buyers were Xorax Family Trust, associated with Quantum's Chief Executive Officer Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by Director Anthony Durkacz. By acquiring 13 shares each, these insiders expanded their collective voting power from 57.01% to approximately 68.22%.

From a regulatory standpoint, the company navigated Canadian Multilateral Instrument 61-101, which governs related-party transactions. By relying on exemptions related to the transaction's size relative to market capitalization, leadership bypassed the formal valuation and minority shareholder approval requirements that typically accompany insider deals. They also skipped the standard 21-day waiting period for a material change report, citing the imminent expiration of a 2025 shareholder authority that permitted the issuance.

"When you see a capital structure where a double-digit percentage of the voting power is exchanged for pocket change, it raises immediate red flags for institutional capital," noted one corporate governance analyst reviewing the filings. "It effectively insulates management from activist pressure or hostile takeovers, regardless of how the common stock performs."

The Minority Pushback

Not all shareholders are quietly accepting this concentration of power. At the AGSM held on November 10, a resolution granting the board ongoing discretion to issue additional Class A shares—expressly to maintain insider voting control at up to 70%—faced notable resistance.

While the measure passed, 34.24% of the disinterested Class B shareholders voted against it.

This vocal minority reflects a growing market-wide intolerance for permanent dual-class structures. Major proxy advisory firms like Institutional Shareholder Services (ISS) and Glass Lewis have increasingly adopted hardline stances against multi-class capital structures with unequal voting rights, particularly those lacking sunset provisions. For retail and institutional investors holding the Class B shares, the reality is stark: their economic exposure is decoupled from their ability to influence corporate direction.

Yet, in the volatile world of clinical-stage biotech, management often argues that insulation from short-term market pressures is necessary to see long-term scientific research through to fruition.

Engineering Survival on the Nasdaq

The governance maneuvers are only one part of Quantum BioPharma's broader defensive playbook. At the same AGSM, shareholders approved two critical special resolutions: authorization for the board to execute a reverse stock split at a ratio of up to 1-for-10, and permission to change the company's name at its discretion.

These are classic hallmarks of a company navigating the harsh realities of the Nasdaq Capital Market. Over the past twelve months, Quantum's stock has endured a brutal 73% decline, recently trading near all-time lows of around $2.04.

While the company currently meets the Nasdaq's $1.00 minimum bid price for continued listing, the cushion is thinning. Furthermore, with Nasdaq recently implementing a strict $4.00 minimum share price requirement for initial listings, the regulatory environment for low-priced equities is tightening. A 1-for-10 reverse split would artificially inflate the share price, safely distancing the company from deficiency notices and potentially attracting institutional investors who are mandated to avoid "penny stocks."

Similarly, a corporate name change often serves as a strategic reset. As Quantum BioPharma shifts its identity away from its earlier associations with psychedelic-derived biopharma toward a more traditional neurodegenerative and metabolic focus, a rebrand can help wash away a battered stock chart and signal a new chapter to the market.

The Science Beneath the Maneuvers

If one strips away the financial engineering, the reverse splits, and the C$81 super-voting shares, what remains is the actual human element: the science. And here, Quantum BioPharma possesses assets that could render its boardroom controversies entirely moot.

The company's crown jewel is Lucid-MS, a patented neuroprotective compound developed by its subsidiary, Lucid Psycheceuticals. Unlike existing multiple sclerosis therapies that primarily focus on suppressing the immune system to prevent flare-ups, Lucid-MS is designed to target the underlying neurodegeneration. By inhibiting protein arginine deiminase 2 (PAD2), the drug aims to prevent and even reverse myelin degradation.

In August 2026, the U.S. Food and Drug Administration cleared the Investigational New Drug (IND) application for Lucid-MS, allowing it to advance into Phase 2 clinical trials. For the 2.8 million people worldwide living with multiple sclerosis, a therapy that could actually repair the nervous system rather than just slow its decline represents a holy grail.

Additionally, Quantum retains a nearly 20% equity stake and a lucrative royalty agreement with Unbuzzd Wellness Inc., a spin-out focusing on clinically validated alcohol metabolism accelerants. This provides a potential non-dilutive revenue stream that could help fund the expensive clinical trials required for Lucid-MS.

Ultimately, Quantum BioPharma is a study in contrasts. On paper, its governance structure is a textbook example of insider entrenchment, achieved for a nominal fee that frustrates minority shareholders and defies modern proxy advisor guidelines. In the laboratory, however, it is pushing the boundaries of neurodegenerative medicine with a drug that has cleared rigorous FDA safety hurdles.

For investors navigating this complex narrative, the pragmatic view requires holding both truths simultaneously. The corporate maneuvering is a survival mechanism designed to keep the lights on and the control tight while the science matures. Whether that C$81 investment goes down in history as a governance overreach or the shrewd preservation of a medical breakthrough will not be decided in the boardroom, but in the clinical trial data yet to come.